{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:36:21Z","timestamp":1791275781665,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T00:00:00Z","timestamp":1133827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/sj.bjc.6602893","type":"journal-article","created":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T05:49:54Z","timestamp":1133934594000},"page":"93-100","source":"Crossref","is-referenced-by-count":37,"title":["Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells"],"prefix":"10.1038","volume":"94","author":[{"given":"J C","family":"Panetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W E","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Cheok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"BF6602893_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng1151","volume":"34","author":"MH Cheok","year":"2003","unstructured":"Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE (2003) Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34: 85\u201390","journal-title":"Nat Genet"},{"key":"BF6602893_CR2","volume-title":"ADAPT II User's Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"DZ D\u2019Argenio","year":"1997","unstructured":"D\u2019Argenio DZ, Schumitzky A (1997) ADAPT II User's Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software (Report). Los Angeles: Biomedical Simulations Resource"},{"key":"BF6602893_CR3","first-page":"5810","volume":"61","author":"T Dervieux","year":"2001","unstructured":"Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV (2001) Differing contribution of thiopurine methyltransferase to mercaptopurine vs thioguanine effects in human leukemic cells. Cancer Res 61: 5810\u20135816","journal-title":"Cancer Res"},{"key":"BF6602893_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/clinchem\/48.1.61","volume":"48","author":"T Dervieux","year":"2002","unstructured":"Dervieux T, Chu Y, Su Y, Pui CH, Evans WE, Relling MV (2002) HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem 48: 61\u201368","journal-title":"Clin Chem"},{"key":"BF6602893_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0025-5564(00)00065-1","volume":"170","author":"F Kozusko","year":"2001","unstructured":"Kozusko F, Chen P, Grant SG, Day BW, Panetta JC (2001) A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math Biosci 170: 1\u201316","journal-title":"Math Biosci"},{"key":"BF6602893_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1124\/mol.64.2.456","volume":"64","author":"NF Krynetskaia","year":"2003","unstructured":"Krynetskaia NF, Brenner TL, Krynetski EY, Du W, Panetta JC, Ching-Hon P, Evans WE (2003) Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2\u2212\/\u2212 mice. Mol Pharmacol 64: 456\u2013465","journal-title":"Mol Pharmacol"},{"key":"BF6602893_CR7","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1096\/fj.00-0089com","volume":"14","author":"NF Krynetskaia","year":"2000","unstructured":"Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV (2000) Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 14: 2339\u20132344","journal-title":"FASEB J"},{"key":"BF6602893_CR8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0026-895X(24)12548-5","volume":"56","author":"NF Krynetskaia","year":"1999","unstructured":"Krynetskaia NF, Krynetski EY, Evans WE (1999) Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol 56: 841\u2013848","journal-title":"Mol Pharmacol"},{"key":"BF6602893_CR9","first-page":"100","volume":"63","author":"EY Krynetski","year":"2003","unstructured":"Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE (2003) A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 63: 100\u2013106","journal-title":"Cancer Res"},{"key":"BF6602893_CR10","first-page":"802","volume":"42","author":"YH Ling","year":"1992","unstructured":"Ling YH, Chan JY, Beattie KL, Nelson JA (1992) Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 42: 802\u2013807","journal-title":"Mol Pharmacol"},{"key":"BF6602893_CR11","first-page":"3852","volume":"43","author":"J Maybaum","year":"1983","unstructured":"Maybaum J, Mandel HG (1983) Unilateral chromatid damage: a new basis for 6-thioguanine cytotoxicity. Cancer Res 43: 3852\u20133856","journal-title":"Cancer Res"},{"key":"BF6602893_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2003-11-3938","volume":"104","author":"J Offman","year":"2004","unstructured":"Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, Burke MM, Sullivan D, Macpherson P, Karran P (2004) Defective DNA mismatch repair in acute myeloid leukemia\/myelodysplastic syndrome after organ transplantation. Blood 104: 822\u2013828","journal-title":"Blood"},{"key":"BF6602893_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1124\/mol.63.5.1094","volume":"63","author":"G Reid","year":"2003","unstructured":"Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094\u20131103","journal-title":"Mol Pharmacol"},{"key":"BF6602893_CR14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","volume":"93","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93: 2817\u20132823","journal-title":"Blood"},{"key":"BF6602893_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1074\/jbc.M204243200","volume":"278","author":"L Somerville","year":"2003","unstructured":"Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, Evans WE, Kriwacki RW (2003) Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 278: 1005\u20131011","journal-title":"J Biol Chem"},{"key":"BF6602893_CR16","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/bi9621573","volume":"36","author":"TR Waters","year":"1997","unstructured":"Waters TR, Swann PF (1997) Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry (Mosc) 36: 2501\u20132506","journal-title":"Biochemistry (Mosc)"},{"key":"BF6602893_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bcp.2004.06.004","volume":"68","author":"H Zeng","year":"2004","unstructured":"Zeng H, Lin ZP, Sartorelli AC (2004) Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210\/VMDRC.06. Biochem Pharmacol 68: 911\u2013921","journal-title":"Biochem Pharmacol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602893.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602893","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602893.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:10:30Z","timestamp":1736154630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,6]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BF6602893"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602893","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,6]]}}}